John R. Proudfoot

John R. Proudfoot

Auto-generated profile, based on publicly available information

John R. Proudfoot

Boehringer Ingelheim Pharmaceuticals Inc., Department of Medicinal Chemistry, 900 Ridgebury Road, PO Box 368, Ridgefield, CT 06877, USA

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JPJohn R. Proudfoot
John R. Proudfoot

1 July 1991 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KHKarl D. Hargrave
Karl D. Hargrave
JPJohn R. Proudfoot
John R. Proudfoot
KGKarl G. Grozinger
Karl G. Grozinger
ECErnest Cullen
Ernest Cullen
SKSuresh R. Kapadia
Suresh R. Kapadia
JAJulian Adams
Julian Adams

1 February 1991 in Biochemistry
Verified
Journal Article
Closed access
JWJoe C. Wu
Joe C. Wu
TWThomas C. Warren
Thomas C. Warren
JAJulian Adams
Julian Adams
JPJohn Proudfoot
John Proudfoot
JSJerry Skiles
Jerry Skiles
PGPeter M. Grob
Peter M. Grob

29 July 2013 in Pure and Applied Chemistry
Verified
Journal Article
Closed access
PDF file
DBDerek R. Buckle
Derek R. Buckle
PEPaul W. Erhardt
Paul W. Erhardt
CGC. Robin Ganellin
C. Robin Ganellin
TKToshi Kobayashi
Toshi Kobayashi
TPThomas J. Perun
Thomas J. Perun
JSJoerg Senn-Bilfinger
Joerg Senn-Bilfinger
The evolution that has taken place in medicinal chemistry practice as a result of major advances in genomics and molecular biology arising from the Human Genome Project has carried with it an extensive additional working vocabulary that has become both integrated and essential terminology for the medicinal chemist. Some of this augmented terminology has been adopted from the many related and interlocked scientific disciplines with which the modern medicinal chemist must be conversant, but many other terms have been introduced to define new concepts and ideas as they have arisen. In this supplementary Glossary, we have attempted to collate and define many of the additional terms that are now considered to be essential components of the medicinal chemist’s expanded repertoire.

1 February 2005 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JPJohn R. Proudfoot
John R. Proudfoot

7 February 2011
Verified
Journal Article
Closed access
PDF file
JPJohn Proudfoot
John Proudfoot
ONOlivier Nosjean
Olivier Nosjean
JBJan Blanchard
Jan Blanchard
JWJohn Wang
John Wang
DBDominique Besson
Dominique Besson
PVPascal Villa
Pascal Villa
Biomolecular screening is now a crucial component of the drug discovery process, and this glossary will be of use to practitioners in the field of screening and to those who interact with the screening community. The glossary contains definitions related to various aspects of the screening process such as assay types, data handling, and relevant technologies. Many of the terms used in this discipline are not covered by existing glossaries, and where they are, the definitions are often not appropriate for this field. Where appropriate, this document provides new or modified definitions to better reflect the new context. The field of biomolecular screening is multidisciplinary in nature, and this glossary, containing authoritative definitions, will be useful not only for regular practitioners, but also for those who make use of data generated during the screening process.